COMP <GO>
OVID vs UNH // GROSS PROFIT MARGIN
Ovid Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: OVID 2
— UNH 8
■ METRIC PARITY
LAST: $2.39 (-5.91%) • MKT CAP: $466.8M
gross-margins
—
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
gross-margins
88.31%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OVID VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OVID | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.50% | 12.38% | -40.88 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.67% | 6.25% | -13.92 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 5.32% | -65.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.53% | -63.53 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 3.33% | +176.67 | OVID | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.46 | 3.09 | +8.37 | OVID | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 55.1 | -6.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $466.8M | $359.43B | -$358.97B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OVID REV | UNH REV | OVID GROSS % | UNH GROSS % | OVID FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.3M | $447.57B | — | 88.7% | -$38.3M | $16.07B |
| FY 2024 | $566.0K | $400.28B | — | 88.3% | -$56.0M | $20.70B |
| FY 2023 | $392.0K | $371.62B | — | 89.6% | -$45.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OVID // BETA —
UNH // BETA 0.33